Use and misuse of waterfall plots

Journal of the National Cancer Institute

Volumn 106, Issue 12, 2014, Pages

  Shao, Tiffany ^a   Wang, Lisa ^a   Templeton, Arnoud J ^a   Jang, Raymond ^a   Vera Badillo, Francisco W ^a   McNamara, Mairead G ^a   Margolis, Myles ^b   Kim, Tae Kyoung ^b   Sinaei, Mehrdad ^b   Shoushtari, Hassan ^b   Tannock, Ian F ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; PANTOPRAZOLE; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; MEASUREMENT ERROR; MEDICAL ONCOLOGIST; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RADIOLOGIST; SOLID TUMOR; TREATMENT RESPONSE; TUMOR VOLUME; CANADA; NEOPLASMS; OBSERVER VARIATION; PATHOLOGY; PROCEDURES; RADIOGRAPHY; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE I AS TOPIC; DATA INTERPRETATION, STATISTICAL; DOXORUBICIN; HUMANS; NEOPLASMS; OBSERVER VARIATION; ONTARIO; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84922393804     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju331     Document Type: Article

References (16)

1. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.
2. Warr D, McKinney S, Tannock I. Influence of measurement error on response rates. Cancer Treat Rep. 1985; 69(10):1127-1132.
3. Warr D, McKinney S, Tannock I. Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response. J Clin Oncol. 1984;2(9):1040-1046.
4. Moertel CG, Hanley JA. The effect of measuring error on the results of therapeutic trials in advanced cancer. Cancer. 1976;38(1):388-394.
5. Erasmus JJ, Gladish GW, Broemeling L, et al. Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol. 2003;21(13):2574-2582.
6. Oxnard GR, Zhao B, Sima CS, et al. Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes. J Clin Oncol. 2011;29(23):3114-3119.
7. Brana I, Ocana A, Chen EX, et al. A phase I Trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: Evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin. Invest. New Drugs. 2014 (in press).
8. Chan JA, Stuart K, Earle CC, et al. Prospective Study of Bevacizumab Plus Temozolomide in Patients With Advanced Neuroendocrine Tumors. J Clin Oncol. 2012;30(24):2963-2968.
9. Wong YN, Litwin S, Vaughn D, et al. Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma. J Clin Oncol. 2012;30(5):3545-3551.
10. Armato SG 3rd, Oxnard GR, MacMahon H, et al. Measurement of mesothelioma on thoracic CT scans: A comparison of manual and computerassisted techniques. Med Phys. 2004;31(5):1105-1115.
11. Armato SG 3rd, Ogarek JL, Starkey A, et al. Variability in mesothelioma tumor response classification. Am J Roentgenol. 2006;186(4):1000-1006.
12. Erasmus JJ, Gladish GW, Broemeling L, et al. Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol. 2003;21(13):2574-2582.
13. Oxnard GR, Zhao B, Sima CS, et al. Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes. J Clin Oncol. 2011;29(23):3114-3119.
14. Choi H, Charnsangavej C, de Castro Faria S, et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. Am J Roentgenol. 2004;183(6):1619-1628.
15. Edeline J, Boucher E, Rolland Y, et al. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer. 2012;118(1):147-156.
16. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24(16):2505-2512.